Organon & Co. (NYSE:OGN) Trading Down 4.4% - Should You Sell?

Organon & Co. (NYSE:OGN - Get Free Report) was down 4.4% during trading on Monday . The company traded as low as $17.21 and last traded at $17.28. Approximately 354,409 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 2,173,754 shares. The stock had previously closed at $18.07.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on OGN shares. Evercore ISI upgraded shares of Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lowered shares of Organon & Co. from a "neutral" rating to an "underweight" rating and upped their target price for the company from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Stock Performance

The stock's 50-day moving average is $19.26 and its 200-day moving average is $20.12. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of 3.36, a P/E/G ratio of 0.85 and a beta of 0.84. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a return on equity of 2,437.43% and a net margin of 20.30%. The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the company posted $0.78 EPS. On average, analysts expect that Organon & Co. will post 4.04 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 6.62%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.'s dividend payout ratio (DPR) is 22.22%.

Institutional Trading of Organon & Co.

Several large investors have recently bought and sold shares of OGN. Wealth Enhancement Advisory Services LLC grew its position in shares of Organon & Co. by 7.8% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 38,669 shares of the company's stock worth $727,000 after buying an additional 2,800 shares in the last quarter. Norden Group LLC acquired a new stake in shares of Organon & Co. during the first quarter worth approximately $355,000. Private Advisor Group LLC grew its position in shares of Organon & Co. by 79.6% during the first quarter. Private Advisor Group LLC now owns 25,318 shares of the company's stock worth $476,000 after buying an additional 11,223 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Organon & Co. during the first quarter worth approximately $231,000. Finally, Janney Montgomery Scott LLC lifted its stake in Organon & Co. by 23.9% during the first quarter. Janney Montgomery Scott LLC now owns 263,051 shares of the company's stock worth $4,945,000 after purchasing an additional 50,788 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.